Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

"They will be launching completed Lympro diagnostics in the US with Quest. Amarantus will retain 100% of the execution and marketing as a sole provider, no sale or partner, too much money for them to do it at this point. I am guessing Quest will have exclusivity with money up front back to AMBS. Overseas is different, nothing will be the same and the Geneva office is part of the marketing strategy to get to EMEA and launch in other countries. The US is the not only country with ALZ, why on earth they would just keep it here would be foolish. They will release it in Q3 and the data will conform to highest standards out there of recognition in accuracy. They will probably not need to dilute if Quest offers up enough to retain exclusivity rights. I suspect you will hear all of this in a marketing plan within the next few weeks, they literally will have to start advertising it soon to get awareness up, like within a few months max. You can't just drop this off at facilities, it will be a major process and they will be disclosing all of this well in advance. JDRF retains rights to allow disclosure on diabetes due to grant provision. Gerald has to let publications come out before he can do anything, so it appears. When JDRF PRs it, it will be way more impactful to AMBS, they reach millions, AMBS reaches thousands. I truly believe you're all finally there. You're looking at 1b+ in intake over the next few years due to lack of competition, keep that in mind when stressing about a .07 pps. They will get CMS approval, no question."

Take it for what its worth